Assam is estimated to
be as the potential key player in driving major turnover for Hetero Healthcare as it is
included among the three selected units for its 7,500 corer drug manufacturing
plant project across India.
Telangana is estimated to launch the plant which is designed to take care
of injectable products along with Assam unit which tablets and capsules plant
is 75 percent ready and is likely to complete by 2017 on March.
This major futuristic plan by Hetero Healthcare to
launch three units in Assam, Andhra Pradesh and Telangana is estimated to garner for 20-25%
turnover. Challenge is higher for Hetero as it exports APIs and formulations to 135 countries with appealing turnover of 60%. Currently
Hetero dominates the HIV segment with 30 % share in international market. In the
domestic retail market Hetero is the first to introduce Fluvir a Swine Flu drug brand
(Oseltamivit). Annual revenue of Hetero from the international market is 90 %.
Hopefully Assam becomes an active player in Hetero's financial success and simultaneously brings profit to the land.
No comments:
Post a Comment
Your highlight can be precious enough to make a change in the present system for better progress of the nation and so make a step to comment.